Learn about the study

• The LANDSCAPE trial is for males between the ages of 12 and 50 who have X-linked retinitis pigmentosa (XLRP) caused by a mutation (or defect) in the RPGR gene.
• The LANDSCAPE trial is studying an investigational (not yet FDA-approved) new gene therapy called laru-zova (also named AGTC-501).
• The study drug (laru-zova) is designed to provide a healthy version of the mutated (or damaged) RPGR gene to allow the cells in the retina to make a healthy RPGR protein.
• The purpose of the LANDSCAPE trial is to assess the safety and tolerability of laru-zova administered in both eyes.

How the LANDSCAPE trial works

Qualification for the study involves confirmation of XLRP with an RPGR gene mutation by genetic testing and a review of your medical history to help determine if you or your child meet eligibility criteria.

• Participants will attend 3 screening visits at a study site. After these visits, if the study doctor determines the participant is eligible and if they wish to proceed, they will have two separate eye surgeries to receive the study drug.
• Once enrolled, participants will undergo surgery to receive an injection of laru-zova in one eye.
• They will then undergo a second surgery on the other eye, between 30 and 60 days after the first surgery.
• Trial participation will last up to 5 years.